Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
[引用][C] Activity of erlotinib when dosed below the maximum tolerated dose forEGFR-mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - cir.nii.ac.jp
Activity of erlotinib when dosed below the maximum tolerated dose forEGFR-mutant lung
cancer: Implications for targeted therapy development | CiNii Research CiNii 国立情報学研究所 …
cancer: Implications for targeted therapy development | CiNii Research CiNii 国立情報学研究所 …
[HTML][HTML] Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - ncbi.nlm.nih.gov
Background Erlotinib is a standard first-line therapy for metastatic non-small-cell lung
cancers (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The …
cancers (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is a standard first-line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - europepmc.org
Background Erlotinib is a standard first-line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - infona.pl
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …